S
Simon Rule
Researcher at University of Plymouth
Publications - 263
Citations - 10013
Simon Rule is an academic researcher from University of Plymouth. The author has contributed to research in topics: Mantle cell lymphoma & Ibrutinib. The author has an hindex of 42, co-authored 255 publications receiving 8169 citations. Previous affiliations of Simon Rule include Peninsula College of Medicine and Dentistry & Derriford Hospital.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: This work presents a meta-analysis of 120 cases of central giant cell granuloma in mice over a 12-month period and shows clear trends in survival and morbidity during the first year of treatment with chemotherapy.
Journal ArticleDOI
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling,Wojciech Jurczak,Mats Jerkeman,Rodrigo Santucci Silva,Chiara Rusconi,Marek Trneny,Fritz Offner,Dolores Caballero,Cristina João,Mathias Witzens-Harig,Georg Hess,Isabelle Bence-Bruckler,Seok-Goo Cho,John Bothos,Jenna D. Goldberg,Christopher Enny,Shana Traina,Sriram Balasubramanian,Nibedita Bandyopadhyay,Steven Sun,Jessica Vermeulen,Aleksandra Rizo,Simon Rule +22 more
TL;DR: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma, and lend further support to the positive benefit-risk ratio for ibrut inib in relapsedor refractors.
Journal ArticleDOI
Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-Blind, Phase 3 Study
Asher Chanan-Khan,Paula Cramer,Fatih Demirkan,Graeme Fraser,Rodrigo Santucci Silva,Sebastian Grosicki,Aleksander Pristupa,Ann Janssens,Jiri Mayer,Nancy L. Bartlett,Marie Sarah Dilhuydy,Halyna Pylypenko,Javier Loscertales,Abraham Avigdor,Simon Rule,Diego Villa,Olga Samoilova,Panagiots Panagiotidis,Andre Goy,Anthony R. Mato,Anthony R. Mato,Miguel A. Pavlovsky,Claes Karlsson,Michelle Mahler,Mariya Salman,Steven Sun,Charles Phelps,Sriram Balasubramanian,Angela Howes,Michael Hallek +29 more
TL;DR: The HELIOS trial assessed the efficacy and safety of adding ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously treated chronic lymphocytic leukaemia or small lymphocytics lymphoma and met the primary endpoint of progression-free survival.
Journal ArticleDOI
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Michael L. Wang,Kristie A. Blum,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Dana Lee,Darrin M. Beaupre,Simon Rule +23 more
TL;DR: With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy.